Place the mouth-dissolving tablet on the tongue. It will rapidly disintegrate in the saliva. Swallow the dissolved medicine with saliva. No water is required for administration.

Ketorolac acts by inhibiting the synthesis of prostaglandins through the non-selective inhibition of cyclooxygenase (COX-1 and COX-2) enzymes. Prostaglandins are mediators of pain, inflammation, and fever, thus reducing these symptoms.

• •Hypersensitivity to Ketorolac or other NSAIDs.
• •Active peptic ulcer, gastrointestinal bleeding or perforation.
• •Advanced renal impairment.
• •Patients at risk for bleeding (e.g., coagulation disorders).
• •Third trimester of pregnancy.

Store below 30°C in a dry place, away from direct sunlight and moisture. Keep out of reach of children.

Symptoms of overdose may include nausea, vomiting, epigastric pain, lethargy, and gastrointestinal bleeding. Management involves symptomatic and supportive treatment. Gastric lavage or activated charcoal may be considered if ingestion is recent.

Pregnancy Category C (D in third trimester or near delivery). Avoid use in the third trimester of pregnancy due to potential for premature closure of the fetal ductus arteriosus. Use with caution in early pregnancy if benefits outweigh risks. Not recommended during breastfeeding as Ketorolac is excreted in breast milk.